Anti-CD20 Antibodies for Treatment of SLE-PAH

PHASE4RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

May 25, 2023

Primary Completion Date

March 31, 2025

Study Completion Date

March 31, 2026

Conditions
Systemic Lupus ErythematosusPulmonary Arterial Hypertension
Interventions
DRUG

Rituximab

Rituximab will be administered as two IV infusions of 1000 mg each, given two weeks apart at Day 0 and Week 2. All subjects will receive 40 mg of prednisone orally the night before and morning of each infusion with diphenhydramine and acetaminophen orally thirty to sixty minutes prior to each infusion of rituximab. Subjects will remain on their baseline standard medical regimen.

Trial Locations (1)

100730

RECRUITING

Peking Union Medical College Hospital, Beijing

All Listed Sponsors
lead

Chinese SLE Treatment And Research Group

OTHER